Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

JAK1 (Janus Kinase 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

PML-JAK1 fusion	Sarcoma	PML-JAK1 fusion	Sarcoma	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3
JAK1 mutation + MSI-H/dMMR	Colorectal Cancer	JAK1 mutation + MSI-H/dMMR	Colorectal Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
JAK1 mutation	Non Small Cell Lung Cancer	JAK1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
JAK1 overexpression	Soft Tissue Sarcoma	JAK1 overexpression	Soft Tissue Sarcoma	ruxolitinib Sensitive: C4 – Case Studies ruxolitinib Sensitive : C4	ruxolitinib Sensitive: C4 – Case Studies ruxolitinib Sensitive : C4
JAK1 P429S	Melanoma	JAK1 P429S	Melanoma	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
JAK1 P429S	Melanoma	JAK1 P429S	Melanoma	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4
JAK1 Q503*	Melanoma	JAK1 Q503*	Melanoma	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4	nivolumab Resistant: C4 – Case Studies nivolumab Resistant : C4
JAK1 Q503*	Melanoma	JAK1 Q503*	Melanoma	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
JAK1 S703I	Hepatocellular Cancer	JAK1 S703I	Hepatocellular Cancer	ruxolitinib Resistant: D – Preclinical ruxolitinib Resistant : D	ruxolitinib Resistant: D – Preclinical ruxolitinib Resistant : D
JAK1 S646F	Acute Lymphocytic Leukemia	JAK1 S646F	Acute Lymphocytic Leukemia	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D	nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical nanoparticle albumin-bound rapamycin Sensitive : D
JAK1 S646F	Childhood B Acute Lymphoblastic Leukemia	JAK1 S646F	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
JAK1 S646F	Acute Lymphocytic Leukemia	JAK1 S646F	Acute Lymphocytic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D